Clinical Trial Protocol for Safety, Efficacy and Feasibility of Implantable Spinal Cord Stimulator System in the Treatment of Limb Motor Dysfunction After Brain Injury

注册号:

Registration number:

ChiCTR2500108641 

最近更新日期:

Date of Last Refreshed on:

2025-09-02 18:01:20 

注册时间:

Date of Registration:

2025-09-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

植入式脊髓神经刺激器系统用于脑损伤后肢体运动功能障碍治疗的安全性和有效性、可行性临床试验方案

Public title:

Clinical Trial Protocol for Safety, Efficacy and Feasibility of Implantable Spinal Cord Stimulator System in the Treatment of Limb Motor Dysfunction After Brain Injury

注册题目简写:

English Acronym:

研究课题的正式科学名称:

植入式脊髓神经刺激器系统用于脑损伤后肢体运动功能障碍治疗的安全性和有效性、可行性临床试验方案

Scientific title:

Clinical Trial Protocol for Safety, Efficacy and Feasibility of Implantable Spinal Cord Stimulator System in the Treatment of Limb Motor Dysfunction After Brain Injury

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张静文 

研究负责人:

李文玲 

Applicant:

Jingwen Zhang 

Study leader:

Wenling Li 

申请注册联系人电话:

Applicant telephone:

+86 177 3287 3136

研究负责人电话:

Study leader's telephone:

+86 138 3111 7829

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

28805565@hebmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

27104413@hebmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

石家庄市新华区和平西路215号

研究负责人通讯地址:

石家庄市新华区和平西路215号

Applicant address:

No. 215 West Heping Road, Xinhua District, Shijiazhuang

Study leader's address:

No. 215 West Heping Road, Xinhua District, Shijiazhuang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河北医科大学第二医院

Applicant's institution:

The Second Hospital of Hebei Medical University

研究负责人所在单位:

河北医科大学第二医院

Affiliation of the Leader:

The Second Hospital of Hebei Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-R142-F1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

河北医科大学第二医院科研伦理委员会

Name of the ethic committee:

The Research Ethics Committee of the Second Hospital of Hebei Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-03-07 00:00:00

伦理委员会联系人:

安雯婷

Contact Name of the ethic committee:

Wenting An

伦理委员会联系地址:

石家庄市新华区和平西路215号

Contact Address of the ethic committee:

No. 215 West Heping Road, Xinhua District, Shijiazhuang

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 311 6600 2826

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河北医科大学第二医院

Primary sponsor:

The Second Hospital of Hebei Medical University

研究实施负责(组长)单位地址:

石家庄市新华区和平西路215号

Primary sponsor's address:

No. 215 West Heping Road, Xinhua District, Shijiazhuang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北

市(区县):

Country:

China

Province:

Hebei

City:

单位(医院):

河北医科大学第二医院

具体地址:

石家庄市新华区和平西路215号

Institution
hospital:

The Second Hospital of Hebei Medical University

Address:

No. 215 West Heping Road, Xinhua District, Shijiazhuang

经费或物资来源:

科研经费

Source(s) of funding:

Scientific Research Funds

Target disease:

Limb motor dysfunction after brain injury

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

初步评估植入式脊髓神经刺激器系统用于脑损伤后肢体瘫痪治疗的安全性和有效性。  

Objectives of Study:

Preliminary evaluation of the safety and efficacy of the implantable spinal cord stimulator system for the treatment of limb paralysis after brain injury.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)脑损伤大于等于6个月,伴有肢体运动功能障碍; (2)年龄≥18周岁且≤70周岁; (3)受试者及家属有强烈意愿进行刺激器植入; (4)受试者有一定的理解与表述能力,自愿参加并签署知情同意书。

Inclusion criteria

(1) The patient has suffered from brain injury for at least 6 months, accompanied by limb motor dysfunction; (2) The patient's age is between 18 and 70 years old (inclusive); (3) The patient and their family members have a strong willingness to undergo stimulator implantation; (4) The patient has a certain ability to understand and communicate, voluntarily participates in the study, and signs the informed consent form.

排除标准:

(1)存在持续的呼吸困难; (2)存在语言或认知障碍; (3)重度抑郁(贝克抑郁量表≥16分); (4)目前有进行性脑部疾病; (5)存在外科手术禁忌症(例如,麻醉剂不良反应史,外科医生认为不适合手术等); (6)体内正在使用其它刺激装置如心脏起搏器或其他神经刺激器等,或有正在使用的其它试验装置或药物; (7)当前或试验期间有热疗法治疗要求; (8)存在明显的关节畸形; (9)妊娠及哺乳期的妇女、在试验期间不能采取适宜的避孕措施的患者。

Exclusion criteria:

(1) Presence of persistent dyspnea; (2) Presence of language or cognitive impairment; (3) Severe depression (Beck Depression Inventory score >= 16); (4) Current progressive brain disease; (5) Presence of surgical contraindications (e.g., history of adverse reactions to anesthetics, deemed unsuitable for surgery by the surgeon, etc.); (6) Having other implanted stimulation devices in the body (such as cardiac pacemakers or other neurostimulators), or using other investigational devices or drugs; (7) Requirement for thermotherapy currently or during the trial period; (8) Presence of significant joint deformities; (9) Pregnant or lactating women, or patients who cannot take appropriate contraceptive measures during the trial period.

研究实施时间:

Study execute time:

From 2025-04-01 00:00:00 To 2027-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-09-10 00:00:00 To 2027-03-01 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

2

Group:

Test group

Sample size:

干预措施:

脊髓电刺激同步人工外骨骼

干预措施代码:

Intervention:

Spinal Cord Electrical Stimulation Synchronized with Artificial Exoskeleton

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China 

Province:

Hebei 

City:

 

单位(医院):

河北医科大学第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Hospital of Hebei Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

FMA-UE(Fugl-Meyer)运动功能评分,与基线相比的变化。

指标类型:

主要指标

Outcome:

The change in the FMA-UE (Fugl-Meyer Assessment for Upper Extremity) motor function score

Type:

Primary indicator

测量时间点:

术后第90天

测量方法:

Measure time point of outcome:

at 90 days post-surgery compared to the baseline

Measure method:

指标中文名:

FMA-UE(Fugl-Meyer)运动功能评分,与基线相比运动功能的变化;

指标类型:

次要指标

Outcome:

The change in motor function as measured by the FMA-UE (Fugl-Meyer Assessment for Upper Extremity) score

Type:

Secondary indicator

测量时间点:

术后180天时

测量方法:

Measure time point of outcome:

at 180 days post-surgery

Measure method:

指标中文名:

痉挛评定量表(改良Ashworth法),与基线相比的变化;

指标类型:

次要指标

Outcome:

The change in the Modified Ashworth Scale (MAS) for spasticity assessment

Type:

Secondary indicator

测量时间点:

术后90天、180天

测量方法:

Measure time point of outcome:

90 and 180 days post-surgery

Measure method:

指标中文名:

上下肢体感诱发电位,与基线相比的变化;

指标类型:

次要指标

Outcome:

The changes in somatosensory evoked potentials (SSEPs) of the upper and lower limbs

Type:

Secondary indicator

测量时间点:

术后90天、180天

测量方法:

Measure time point of outcome:

90 and 180 days post-surgery

Measure method:

指标中文名:

上下肢运动诱发电位,与基线相比的变化;

指标类型:

次要指标

Outcome:

The changes in motor evoked potentials (MEPs) of the upper and lower limbs

Type:

Secondary indicator

测量时间点:

术后90天、180天

测量方法:

Measure time point of outcome:

at 90 and 180 days post-surgery

Measure method:

指标中文名:

肌电图(EMG)测试,与基线相比的变化;

指标类型:

次要指标

Outcome:

The changes in electromyography (EMG) tests of the upper and lower limbs

Type:

Secondary indicator

测量时间点:

术后90天、180天时

测量方法:

Measure time point of outcome:

90 and 180 days post-surgery

Measure method:

指标中文名:

脑电图(EEG)测试,与基线相比的变化。

指标类型:

次要指标

Outcome:

The changes in electroencephalogram (EEG) tests

Type:

Secondary indicator

测量时间点:

术后90天、180天时

测量方法:

Measure time point of outcome:

at 90 and 180 days post-surgery

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

无/None

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表 电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and an electronic data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-09-02 18:01:02